# Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）

> **NCT03735264** · PHASE2 · UNKNOWN · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 46 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib Hydrochloride plus Docetaxel

## Key facts

- **NCT ID:** NCT03735264
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-15
- **Primary completion:** 2020-10-14
- **Final completion:** 2020-10-15
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2018-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03735264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03735264, "Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03735264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*